Background
Gilead Sciences, Inc., a research-based bio-pharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company’s products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology.
The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; and oNKo-innate Pty. Ltd.
The company was founded in 1987 and is headquartered in Foster City, California.
Sector: Healthcare
Industry: Drug Manufacturers—General
Market Cap(M$): 104,675
52 Week High: 85.97$
52 Week Low: 60.89$
Forward PE: 13.13$
Trailing PE: 19.70$
Q Earning Growth: 897.67%
pegRatio: 19.70
Analytics Recommendations
| Date | Firm | To Grade | From Grade | Action |
| 09/03/2020 | RBC Capital | Outperform | Top Pick | down |
| 18/03/2020 | DZ Bank | Buy | Hold | up |
| 19/03/2020 | Wells Fargo | Overweight | main | |
| 20/03/2020 | Piper Sandler | Overweight | Neutral | up |
| 07/04/2020 | Cantor Fitzgerald | Overweight | reiterate | |
| 17/04/2020 | Baird | Outperform | Neutral | up |
| 17/04/2020 | CFRA | Sell | Hold | down |
| 20/04/2020 | BMO Capital | Market Perform | Outperform | down |
| 20/04/2020 | Wells Fargo | Equal-Weight | Overweight | down |
| 27/04/2020 | UBS | Neutral | Buy | down |
Earning and Revenue
The stock has been on a very volatile uptrend starting mid-February, once the 67$ level has been broken to the upside, the volatility, if fed by rumors that the company has a successful drug to treat the coronavirus, the price of the stock, will move up and down in strong moves as the rumors continue until we have verified announcement by the company, we maintain our bullish position on GILD as long as the price remains above the 75$ levels.
Trade Smartly,
Alon